Relmada Therapeutics, Inc. (NASDAQ: RLMD) today announced the pricing of an offering of 3,333,334 shares of its common stock at a public offering price of $30.00 per share in an underwritten offering. The gross proceeds to Relmada from the offering, before deducting underwriting discounts and commissions and other estimated expenses payable by Relmada, are expected to be $100,000,020. In addition, Relmada has granted the underwriters a 30-day option to purchase up to an additional 500,000 shares of Relmada's common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 6, 2019, subject to customary closing conditions.

Jefferies, SVB Leerink and Guggenheim Securities are acting as joint book-running managers for the offering.

Relmada intends to use the net proceeds from the offering to fund research and development activities for its clinical development programs related to Relmada's lead product candidate, REL-1017 (d-methadone), which is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications, as well as for working capital and general corporate purposes.